INCB 13739

Drug Profile

INCB 13739

Alternative Names: INCB013739; INCB13739

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antihyperglycaemics
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 05 Aug 2015 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus in Puerto Rico, USA (PO)
  • 09 Jun 2009 Efficacy, safety and pharmacodynamics data from a phase IIb trial in Type-2 diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)
  • 10 Jun 2008 Final pharmacodynamics and adverse events data from a phase IIa trial in Type 2 diabetes presented at the 68th Annual Scientific Sessions of the American Diabetes Association (ADA-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top